AGO Algorithms for the Treatment of Breast Cancer: Update 2021

Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individua...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeweiss, Andreas, Fasching, Peter A., Fehm, Tanja, Gerber, Bernd, Jackisch, Christian, Loibl, Sibylle, Schmidt, Marcus, Stickeler, Elmar, Wöckel, Achim, Janni, Wolfgang, Müller, Volkmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494518/
https://www.ncbi.nlm.nih.gov/pubmed/34629489
http://dx.doi.org/10.1055/a-1519-7089
_version_ 1784579327552126976
author Schneeweiss, Andreas
Fasching, Peter A.
Fehm, Tanja
Gerber, Bernd
Jackisch, Christian
Loibl, Sibylle
Schmidt, Marcus
Stickeler, Elmar
Wöckel, Achim
Janni, Wolfgang
Müller, Volkmar
author_facet Schneeweiss, Andreas
Fasching, Peter A.
Fehm, Tanja
Gerber, Bernd
Jackisch, Christian
Loibl, Sibylle
Schmidt, Marcus
Stickeler, Elmar
Wöckel, Achim
Janni, Wolfgang
Müller, Volkmar
author_sort Schneeweiss, Andreas
collection PubMed
description Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape.
format Online
Article
Text
id pubmed-8494518
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-84945182021-10-07 AGO Algorithms for the Treatment of Breast Cancer: Update 2021 Schneeweiss, Andreas Fasching, Peter A. Fehm, Tanja Gerber, Bernd Jackisch, Christian Loibl, Sibylle Schmidt, Marcus Stickeler, Elmar Wöckel, Achim Janni, Wolfgang Müller, Volkmar Geburtshilfe Frauenheilkd Therapy options shown in the algorithms are based on the current AGO recommendations, but cannot represent all evidence-based treatment options, since prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. In individual cases, other evidence-based treatment options may also be appropriate and justified. Regardless of approval status, the algorithms only take into account drugs that were available in Germany at the time the algorithm was last updated. Here we present the 2021 update of AGO treatment algorithms for early and metastatic breast cancer, which are intended to intensify structured treatment decision by providing reproducible and evidence-based treatment paths and may be helpful for a broad treatment landscape. Georg Thieme Verlag KG 2021-10 2021-10-06 /pmc/articles/PMC8494518/ /pubmed/34629489 http://dx.doi.org/10.1055/a-1519-7089 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Schneeweiss, Andreas
Fasching, Peter A.
Fehm, Tanja
Gerber, Bernd
Jackisch, Christian
Loibl, Sibylle
Schmidt, Marcus
Stickeler, Elmar
Wöckel, Achim
Janni, Wolfgang
Müller, Volkmar
AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title_full AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title_fullStr AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title_full_unstemmed AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title_short AGO Algorithms for the Treatment of Breast Cancer: Update 2021
title_sort ago algorithms for the treatment of breast cancer: update 2021
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494518/
https://www.ncbi.nlm.nih.gov/pubmed/34629489
http://dx.doi.org/10.1055/a-1519-7089
work_keys_str_mv AT schneeweissandreas agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT faschingpetera agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT fehmtanja agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT gerberbernd agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT jackischchristian agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT loiblsibylle agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT schmidtmarcus agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT stickelerelmar agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT wockelachim agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT janniwolfgang agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT mullervolkmar agoalgorithmsforthetreatmentofbreastcancerupdate2021
AT agoalgorithmsforthetreatmentofbreastcancerupdate2021

Ejemplares similares